Affinergy Inc.
This article was originally published in Start Up
Executive Summary
Affinergy has--patented and in the freezer--peptide binders that stick specifically to the common materials of which medical implants are made, for example, collagen, titanium and stainless steel. These are the starting point for the company's device coating platform. The other part of the biocoating, which attaches to the device-binding peptide by a linker, is a peptide that binds to a specific protein or cell type of interest to a partner.
You may also be interested in...
Biocoatings: Not Just the Icing on the Cake
The successful commercialization of drug-eluting stents (DES) has done much to pave the way for the biocoating industy. DES not only helped establish a new regulatory body to facilitate device-drug reviews, the FDA Office of Combination Products, they also proved that biocoated devices could take market share from uncoated products, command premium pricing and premium reimbursement.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.